Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Julian J. Weiss, Samuel J. Yates, Talha Badar, Anand Ashwin Patel, Eric S. Winer, Mark R. Litzow, Wei Cheng, Chenyu Lin, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 1489.

https://doi.org/10.1182/blood-2024-206670

Published: 2024

Journal Articles

Leukemia Physician's Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia

Yenny Alejandra Moreno Vanegas, Suhaib Younis Mohamed El Khatib, Brooke Hisrich, Alexander Coltoff, Rory M. Shallis, Anand Ashwin Patel, Jan Philipp Bewersdorf, Timothy S. Oh, Yasmin Abaza, Charles Foucar, Aaron D. Goldberg, Adam S. Duvall, Ehab L. Atallah, Mark R. Litzow, Talha Badar

Blood (2024) 144 (Supplement 1): 1487.

https://doi.org/10.1182/blood-2024-205782

Published: 2024

Journal Articles

Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia

Cameron J. Hunter, Jan Philipp Bewersdorf, Lourdes Mendez, Nikolai A. Podoltsev, Amer M. Zeidan, William Eighmy, Heidi Roeder, Maricar Malinis, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 1480.

https://doi.org/10.1182/blood-2024-211250

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study

Adam Julian Cohen-Nowak, Alexander Coltoff, Anand Ashwin Patel, Ehab L. Atallah, Mobachir El Kettani, John Wang, Emily Symes, Girish Venkataraman, Alexa Siddon, Emily Giever, Rory M. Shallis, Jessica Kaplan Altman, Kirsten Bell-Burdett, Talha Badar, Barina Aqil, Yasmin Abaza

Blood (2024) 144 (Supplement 1): 2801.

https://doi.org/10.1182/blood-2024-199377

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Jan Philipp Bewersdorf, Vanessa Hasle, Rory M. Shallis, Ethan G. Thompson, Daniel Lopes De Menezes, Shelonitda Rose, Isaac W. Boss, Lourdes Mendez, Nikolai A. Podoltsev, Maximilian Stahl, Tariq Kewan, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2024-194929

Published: 2024

Journal Articles

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood (2024) 144 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2024-205812

Published: 2024

Journal Articles

Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia

Cameron J. Hunter, Jan Philipp Bewersdorf, Lourdes Mendez, Nikolai A. Podoltsev, Amer M. Zeidan, William Eighmy, Heidi Roeder, Maricar Malinis, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2024-211426

Published: 2024

Journal Articles

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2024-211623

Published: 2024

Journal Articles

Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

Blood (2024) 144 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2024-204467

Published: 2024

Journal Articles

The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study

Blood (2024) 144 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2024-205581

Published: 2024

Journal Articles

Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Blood (2024) 144 (Supplement 1): 4267.

https://doi.org/10.1182/blood-2024-202744

Published: 2024

Journal Articles

Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 1508.

https://doi.org/10.1182/blood-2024-207045

Published: 2024

Journal Articles

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Samuel J. Yates, Julian J. Weiss, Abigail Sneider, Emily Geramita, Guru Subramanian Guru Murthy, Talha Badar, Annie Im, Chenyu Lin, Wei Cheng, Eric S. Winer, Yasmin Abaza, Mark R. Litzow, Ehab L. Atallah, Alok Swaroop, Anand Ashwin Patel, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 447.

https://doi.org/10.1182/blood-2024-207116

Published: 2024

Journal Articles

Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States

Kunal C Potnis, Satoko Ito, Kishan Patel, Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, Amer M. Zeidan, Jan Philipp Bewersdorf, George Goshua

Blood (2024) 144 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2024-204312

Published: 2024

Journal Articles

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Blood (2024) 144 (Supplement 1): 1787.

https://doi.org/10.1182/blood-2024-197898

Published: 2024

Journal Articles

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Blood (2024) 144 (Supplement 1): 5174.

https://doi.org/10.1182/blood-2024-198914

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Blood (2024) 144 (Supplement 1): 736.

https://doi.org/10.1182/blood-2024-210370

Published: 2024

Journal Articles

Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia

Abdulrahman Alhajahjeh, Kishan Patel, Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, Amer M. Zeidan, George Goshua, Jan Philipp Bewersdorf

Blood (2024) 144 (Supplement 1): 788.

https://doi.org/10.1182/blood-2024-201535

Published: 2024

NARROW

Association between Body Mass Index and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Leukemia Physician's Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia

Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia

Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study

Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States

Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only